Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02853331 · OUTCOME

Overall Survival (OS) Rate at Month 12 in All Participants

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) · Source last updated 2026-02-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Month 12

What was measured

The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 12 is presented.

Analysis population: The analysis population consisted of all randomized participants.

Groups in this outcome

Pembrolizumab + Axitinib

Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.

Sunitinib

Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pembrolizumab + Axitinib432
Sunitinib429

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Pembrolizumab + Axitinib89.9Not reported86.492.4Not reported
Sunitinib78.3Not reported73.882.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        86.4
        upper Limit
        92.4
        value
        89.9
      2. group Id
        OG001
        lower Limit
        73.8
        upper Limit
        82.1
        value
        78.3
denoms
  1. counts
    1. group Id
      OG000
      value
      432
    2. group Id
      OG001
      value
      429
    units
    Participants
description
The OS rate was determined for all participants at Month 12 and was defined as the time from randomization to death due to any cause. Participants were censored at the date of their last assessment. The OS rate at Month 12 is presented.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
    id
    OG000
    title
    Pembrolizumab + Axitinib
  2. description
    Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.
    id
    OG001
    title
    Sunitinib
param Type
NUMBER
population Description
The analysis population consisted of all randomized participants.
reporting Status
POSTED
time Frame
Month 12
title
Overall Survival (OS) Rate at Month 12 in All Participants
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice